And recent news from Lululemon offers us reason to be optimistic. The company reported a successful holiday season, allowing it to raise its fourth-quarter 2024 revenue, earnings per share, and gross margin guidance. The new forecast implies 11% to 12% revenue growth year over year.

Biote: Revolutionizing Hormone Optimization Biote (NYSE: BTMD) represents an innovative play in the growing hormone optimization market.

To the disappointment of buy-and-hold investors, 2025 is shaping up to be a year where nimble traders are likely to see the biggest gains. That said, there’s nothing wrong with the steady performance offered by blue-chip stocks—a sound strategy for many investors.